Office based non-oncology urology trials
Richard W. Casey, MD,¹ Jack Barkin, MD²
¹The Male Health Centre, Oakville, Ontario, Canada
²Humber River Regional Hospital, University of Toronto, Toronto, Ontario, Canada

## BENIGN PROSTATIC HYPERPLASIA

A PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF A SINGLE TREATMENT OF 100 U, 200 U, or 300 U BOTOX® COMPARED WITH PLACEBO INJECTED INTO THE PROSTATE TO TREAT LOWER URINARY TRACT SYMPTOMS (LUTS) IN PATIENTS DUE TO BENIGN PROSTATIC HYPERPLASIA

**Trial ID:** 191622-517-05  
**Coordination:** CMX Research Inc.  
**Trial design:** A phase II study assessing the safety and efficacy of a single treatment of BOTOX® compared with placebo injected into the prostate.  
**Patient population:** Lower urinary tract symptoms due to benign prostatic hyperplasia.  
**Sample size:** n = 300

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF OZARELIX, IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS (LUTS) DUE TO BENIGN PROSTATIC HYPERTROPHY (BPH)

**Trial ID:** SPI-153-08-1  
**Coordination:** CMX Research Inc.  
**Trial design:** To evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hypertrophy (BPH) in men as assessed by the International Prostate Symptom Score (IPSS) at week 14.  
**Patient population:** Male patients at least 50 years of age with symptomatic BPH-LUTS.  
**Sample size:** n = 860

CETORELIX PAMOATE (AEZS-102) IN PATIENTS WITH SYMPTOMATIC BPH: AN OPEN-LABELED SAFETY AND EFFICACY ASSESSMENT STUDY

**Trial ID:** AEZS-102-041  
**Coordination:** CMX Research Inc.  
**Trial design:** Phase III study to evaluate the safety and efficacy of a CET pamoate IM 90 mg regimen given as 52 + 26 mg 2 weeks apart.  
**Patient population:** Male subjects, age 50 or older show present with BPH symptoms.  
**Sample size:** n = 500
**OVERACTIVE BLADDER**

12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT WITH OVERACTIVE BLADDER

**Trial ID:** AO221046

**Coordination:** CMX Research Inc.

**Trial design:** Phase IIIb/IV study to compare the efficacy of fesoterodine with that of placebo and of tolterodine ER in subjects with overactive bladder, after 12 weeks of treatment.

**Patient population:** Male or female subjects who present with symptoms of OAB.

**Sample size:** n = 1675

A DOUBLE-BLIND, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFECT OF TREATMENT WITH TOPICALLY ADMINISTERED OXYBUTYNYL GEL IN PATIENTS WITH URINARY FREQUENCY, AND URGE AND MIXED URINARY INCONTINENCE WITH A PREDOMINANCE OF URGE INCONTINENCE EPISODES

**Trial ID:** 20070060

**Coordination:** CMX Research Inc.

**Trial design:** Phase III study to compare the effects of oxybutynin gel (56 mg oxybutynin/day) and oxybutynin gel (84 mg oxybutynin/day) to placebo gel.

**Patient population:** Male or female subjects over the age of 18, with OAB symptoms of urge and/or mixed UI with a predominance of urge incontinence (based on the investigator’s determination) for at least 3 months.

**Sample size:** n = 600

A DOUBLE-BLIND, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFECT OF TREATMENT WITH TOPICALLY ADMINISTERED OXYBUTYNYL GEL IN PATIENTS WITH URINARY FREQUENCY, AND URGE AND MIXED URINARY INCONTINENCE WITH A PREDOMINANCE OF URGE INCONTINENCE EPISODES

**Trial ID:** 20070060

**Coordination:** CMX Research Inc.

**Trial design:** To evaluate the effects of oxybutynin gel (at doses of 56 mg oxybutynin/day and 84 mg oxybutynin/day), relative to placebo in patients with urge and mixed urinary incontinence with a predominance of urge incontinence on:

**Patient population:** Patients with urge and/or mixed urinary incontinence with a predominance of urge incontinence episodes (at least 2:1 urge to stress incontinence episodes).

**Sample size & endpoint:** n = 600, the change from baseline to week 12 in the number of urinary incontinence episodes (UIE) per week, as determined from a 3-day patient daily diary.
CLINICAL TRIALS

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY OF VARDENAFIL 10 MG TWICE DAILY TO ASSESS THE EFFECT ON URODYNAMICS IN PATIENTS WITH OVERACTIVE BLADDER (DETRUSOR OVERACTIVITY)

Trial ID: BAY-38-9456
Coordination: CMX Research Inc.
Trial design: To determine the therapeutic effect of vardenafil 10 mg taken twice daily (BID) on overactive bladder by means of urodynamic measurements (filling cystometry and pressure flow investigations).
Patient population: Subjects with overactive bladder (with or without urge incontinence) for at least 6 months. Forty percent subjects recruited should be male.
Sample size & endpoint: n = 481, change from baseline in bladder volume at first detrusor contraction. Change in the number of daily micturition as reported in the patient diaries.

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE CONTROLLED, MULTICENTER LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE BETA-3 AGONIST YM178 (50 MG QD AND 100 MG QD) IN SUBJECTS WITH SYMPTOMS OF OVERACTIVE BLADDER

Trial ID: YM178-CL-049
Coordination: CMX Research Inc.
Trial design: To assess the safety and tolerability of long-term treatment with YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder.
Patient population: The study will randomize female and male subjects at least 18 years of age, who have symptoms of overactive bladder (urinary frequency and urgency with or without incontinence for at least 3 months).
Sample size & endpoint: n = 2500, approximately 2500 subjects will be enrolled. This number is not based on a formal sample size calculation. Primarily, subjects who completed the pivotal studies (178-CL-046 or 178-CL-047) will be enrolled. However, subjects not participating in these studies may be enrolled as well.

A PLACEBO CONTROLLED RANDOMIZED, 12-WEEK, DOSE-RANGING, DOUBLE-BLIND STUDY VERSUS PLACEBO USING TOLTERODINE AS A STUDY CALIBRATOR, TO EVALUATE EFFICACY AND SAFETY OF SSR240600C IN WOMEN WITH OVERACTIVE BLADDER INCLUDING URGE URINARY INCONTINENCE

Trial ID: DRI6271
Coordination: CMX Research Inc.
Trial design: A multi-center randomized, double-blind, 5-arm, parallel group study comparing three doses of SSR240600 (25, 50, and 100 mg) to placebo using tolterodine as a calibrator. The study consists of 3 phases: a) screening period of 1 week, b) double-blind treatment period of 12 weeks, and c) follow-up period of 2 weeks.
Patient population: Females ≥ 18 and ≤ 70 years of age with diagnosis of overactive bladder with symptoms of urgency with urge incontinence and frequency (≥ 1 urgency episode per day, ≥ 8 micturitions per day, ≥ 5 urge urinary incontinence (UUI) episodes/week), which may be associated with nocturia, but without bladder pain.
Sample size: n = 800
THE EFFECTS OF INTRAVESICAL INJECTION OF BOTOX® ON PATIENTS WITH URINARY URGENCY AND FREQUENCY WITHOUT INCONTINENCE DUE TO OVERACTIVE BLADDER

Trial ID: ALG-CMX-01
Coordination: CMX Research Inc.
Trial design: The study proposes to examine the efficacy of Botox® in dry OAB patients by using standard voiding diaries and quality of life (QOL) questionnaires. In addition, safety and the duration of the clinical response will be monitored.
Patient population: Urinary frequency and urgency without incontinence.
Sample size & endpoint: n = 20, the primary endpoint is the number of urinary urgency episodes per day as recorded in a 3-day bladder diary at 3 months.

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSES OF DR-3001 VERSUS PLACEBO IN WOMEN WITH OVERACTIVE BLADDER

Trial ID: DR-OXY-301
Coordination: Duramed Research Inc.
Trial design: Phase III to evaluate the efficacy and safety of DR-3001 (Oxybutynin Vaginal Ring releasing 4 mg or 6 mg/day) versus placebo over 12 weeks, in women diagnosed with overactive bladder who have symptoms of pure or predominantly urge incontinence, urgency and frequency.
Patient population: 1161
Sample size & endpoint: n = 1548, the primary measure of efficacy will be the change from Visit 1 (Baseline) to Visit 5 (Treatment Week 12/Early Withdrawal) in total weekly number of incontinence episodes.

A PHASE IIIb STUDY COMPARING THE EFFICACY OF FESOTERODINE TO PLACEBO AND TOLTERODINE ER IN SUBJECTS WITH OVERACTIVE BLADDER AFTER 12 WEEKS OF TREATMENT

Trial ID: A0221008
Coordination: CMX Research Inc.
Trial design: A 12-week, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder.
Patient population: Overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
Sample size & endpoint: n = 1675, primary endpoint: change in mean number of urgency urinary incontinence (UUI) episodes per 24 hours at week 12 relative to the baseline.

A PHASE II STUDY TO ASSESS THE EFFICACY AND SAFETY OF MODIFIED RELEASE UK-369,003 IN THE TREATMENT OF MEN WITH STORAGE LOWER URINARY TRACT SYMPTOMS (LUTS) WITH AND WITHOUT ERECTILE DYSFUNCTION (ED).

Trial ID: A3711047
Coordination: CMX Research Inc.
Trial design: A multi-national, multi-center, double-blind, randomized, placebo-controlled, parallel group phase II study with five treatment arms.
Patient population: Male aged 18 and above, with documented clinical diagnosis of OAB, with mean urinary frequency ≥ 8 times/24 hours, and mean number of urgency episodes with or without urgency incontinence ≥1 episode/24 hours.
Sample size & endpoint: n = 300, efficacy endpoints based on: LUTS diary scores, International Prostate Symptom Score, Overactive Bladder questionnaire, Patient Perception of Bladder Condition, International Consultation on Incontinence Questionnaire, Erectile Function domain of International Index of Erectile Function, Quality of Erection questionnaire, Patient Reported Treatment Impact questionnaire, Population Pharmacokinetics.
INTERSTITIAL CYSTITIS

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP EVALUATION OF THE EFFICACY AND SAFETY OF URACYST® (INTRAVESICAL SODIUM CHONDROITIN SULFATE) VERSUS VEHICLE PLACEBO IN PATIENTS WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS)

Trial ID: UR07001
Coordination: CMX Research Inc.
Trial design: Prospective, randomized, double-blind, vehicle placebo-controlled, 12-week study, including a 6-week treatment period, followed by a 6-week follow-up period.
Patient population: Male and females at least 18 years of age and have a clinical diagnosis of IC/PBS and who meet eligibility criteria.
Sample size: n = 50

A PHASE II, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME

Trial ID: A4291043
Coordination: CMX Research Inc.
Trial design: Phase II - proof of concept study to evaluate efficacy and safety of study drug.
Sample size: n = 129

ERECTILE DYSFUNCTION

PIVOTAL PHASE III TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF AN ORODISPERISIBLE TABLET VARDENAFIL VERSUS PLACEBO IN THE TREATMENT OF MEN WITH ERECTILE DYSFUNCTION (ED) - A FIXED-DOSE, DOUBLE-BLIND, RANDOMIZED MULTI-CENTER TRIAL N- POTENT 2

Trial ID: 12094
Coordination: CMX Research Inc.
Trial design/treatment: This randomized double-blind, placebo controlled, parallel-arm international, multi-center study will examine the efficacy and safety of BAY 389456 Orodispersible tablet versus placebo in males 18 years and older with erectile dysfunction.
Patient population: Male subject 18 years of age and older and have a clinical diagnosis of ED and who meet eligibility criteria.
Sample size: n = 280

PREMATURE EJACULATION

A PHASE IIb, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH OPEN-LABEL FOLLOW ON, TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF PSD502 IN SUBJECTS WITH PREMATURE EJACULATION (PE)

Trial ID: PSD502-PE-002
Coordination: CMX Research Inc.
Trial Design: Phase IIb, multi-center, randomized, double-blind, placebo-controlled study. Subjects will be randomized to PSD502 or placebo in a 2:1 ratio.
Patient Population: Male subjects with PE according to Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria, aged 18 and over.
Sample Size: n = 240-300